Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  irinotecan hydrochloride
Find trials that include:  Any drugs shown
Results 1-25 of 65 for your search:
Start Over
Risk-Based Therapy in Treating Younger Patients with Newly Diagnosed Liver Cancer
Status: Active
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 21 and under
Trial IDs: AHEP0731, NCI-2011-01975, CDR0000654889, NCT02265692, COG-AHEP0731, NCT00980460
Combination Chemotherapy with or without Stereotactic Body Radiation Therapy in Treating Patients with Locally Advanced Pancreatic Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: PANC0015, NCI-2013-01658, 5136, NCT01926197
Combination Chemotherapy with or without Temsirolimus in Treating Patients with Intermediate Risk Rhabdomyosarcoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 40 and under
Trial IDs: ARST1431, NCI-2015-01644, NCT02567435
A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CanStem303C, NCI-2016-01385, 2016-001627-31, BB608-303CRC, NCT02753127
Guadecitabine and Irinotecan Hydrochloride or Regorafenib or TAS-102 Alone in Treating Patients with Previously Treated Metastatic Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NA_00085870, J1369, NCI-2013-02005, j1369, NA_00085870, CIR00004735, CIR00013885, CIR0002117, NCT01896856
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
S1313, Combination Chemotherapy with or without PEGPH20 in Treating Patients with Newly Diagnosed Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: S1313, NCI-2013-01776, PS1313_A09PAMDREVW01, NCT01959139
WEE1 inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients with Relapsed or Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1312, NCI-2014-00547, NCT02095132
Gemcitabine Hydrochloride, Docetaxel, Capecitabine, Cisplatin, and Irinotecan Hydrochloride in Treating Patients with Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 76
Trial IDs: J14161, NCI-2015-00235, NCT02324543
Genetic Analysis-Guided Dosing of FOLFIRABAX in Treating Patients with Advanced Gastrointestinal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-0595, NCI-2014-02407, NCT02333188
Neoadjuvant GMCI Plus mFOLFIRINOX and Chemoradiation for Non-Metastatic Pancreatic Adenocarcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 76
Trial IDs: PaTK02, NCI-2015-00859, NCT02446093
Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients with Untreated Metastatic Pancreatic Cancer
Status: Not yet active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 265214, NCI-2015-01597, NCT02575508
Bispecific Antibody Armed Activated T-cells with Aldesleukin and Sargramostim in Treating Patients with Locally Advanced or Metastatic Pancreatic Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-100, NCI-2015-01942, 1510014428, NCT02620865
Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Sym004-09, NCI-2016-00919, NCT02568046
Irinotecan Hydrochloride and Cetuximab with or without Ramucirumab in Treating Patients with Advanced Colorectal Cancer with Progressive Disease after Treatment with Bevacizumab-Containing Chemotherapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: E7208, NCI-2011-02018, ECOG-E7208, CDR0000666736, NCT01079780
Combination Chemotherapy with or without Panitumumab in Treating Patients with Colorectal Cancer with Liver Metastases Previously Treated with Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-137, NCI-2011-00375, NCT01312857
Combination Chemotherapy and Radiation Therapy before Surgery in Treating Patients with Pancreatic Cancer That May Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-328, NCI-2012-01540, NCT01591733
Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients with Pancreatic Cancer That May Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2011.007, NCI-2012-01916, HUM00047389, HUM 47389, NCT01661088
Irinotecan Hydrochloride and Temozolomide with Temsirolimus or Dinutuximab in Treating Younger Patients with Refractory or Relapsed Neuroblastoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Children
Trial IDs: ANBL1221, NCI-2012-03125, PANBL1221_A08PAMDREVW01, COG-ANBL1221, CDR0000745188, NCT01767194
Panitumumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Combination Chemotherapy and Bevacizumab
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: OSU-11131, NCI-2013-00432, 2012C0033, NCT01814501
Combination Chemotherapy and Losartan Potassium Followed by Radiation Therapy and Capecitabine in Treating Patients with Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-051, NCI-2013-01816, NCT01821729
Combination Chemotherapy Followed by Ipilimumab and Vaccine Therapy in Treating Patients with Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9478, NCI-2013-02238, FD-R-004819-01, NA_00086350, J13108, NCT01896869
Combination Chemotherapy, Gemcitabine Hydrochloride, and Radiation Therapy before Surgery in Treating Patients with Borderline Resectable Pancreatic Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-570, NCI-2013-01213, 12-017, NCT01897454
Start Over